Table 2.
Demographics for patients utilizing Technology Recordings to better Understand BMT (TRU-BMT)
| Empty Cell | Total (n = 30) |
Adherent (n = 11) |
Nonadherent(n = 19) | P value |
|---|---|---|---|---|
| Age, median (IQR) | 58 (45-62) | 61 (19-68) | 54 (19-66) | .33 |
| Gender | .69 | |||
| Female | 9 (30%) | 4 (36%) | 5 (26%) | |
| Male | 21 (70%) | 7 (64%) | 14 (74%) | |
| Race | .28 | |||
| Black | 3 (10%) | 0 (0%) | 3 (16%) | |
| White | 27 (90%) | 11 (100%) | 16 (84%) | |
| Hispanic | >.99 | |||
| No | 29 (97%) | 11 (100%) | 18 (95%) | |
| Unknown | 1 (3%) | 0 (0%) | 1 (5%) | |
| Education Level | .99 | |||
| 4-year college or higher | 15 (50%) | 6 (55%) | 9 (47%) | |
| Less than 4-year college | 15 (50%) | 5 (45%) | 10 (53%) | |
| Transplant Diagnosis | .20 | |||
| ALL/AML | 6 (20%) | 4 (36%) | 2 (11%) | |
| Lymphoma | 8 (27%) | 4 (36%) | 4 (21%) | |
| MDS/MPN | 11 (37%) | 2 (18%) | 9 (47%) | |
| Other | 5 (16%) | 1 (9%) | 4 (21%) | |
| Conditioning Regimen | .51 | |||
| Myeloablative | 21 (70%) | 9 (82%) | 12 (63%) | |
| Non-myeloablative | 6 (20%) | 2 (18%) | 4 (21%) | |
| Reduced Intensity | 3 (10%) | 0 (0%) | 3 (16%) | |
| Graft | .99 | |||
| BM | 4 (13%) | 1 (9%) | 3 (16%) | |
| Cord | 4 (13%) | 1 (9%) | 2 (11%) | |
| PBPC | 23 (74%) | 9 (82%) | 14 (74%) | |
| KPS | .14 | |||
| Unknown | 1 (3%) | 0 (0%) | 1 (5%) | |
| 80 | 7 (23%) | 2 (18%) | 5 (26%) | |
| 90 | 17 (57%) | 5 (46%) | 12 (63%) | |
| 100 | 5 (17%) | 4 (36%) | 1 (5%) | |
| HCT-CI (mean, range) | .42 | |||
| ≤ 3 | 21 (70%) | 9 (82%) | 12 (63%) | |
| >3 | 9 (30%) | 2 (18%) | 7 (37%) | |
| DRI | .89 | |||
| High | 2 (7%) | 1 (9%) | 1 (5%) | |
| Intermediate | 23 (77%) | 9 (82%) | 14 (74%) | |
| Low | 3 (10%) | 1 (9%) | 2 (11%) | |
| N/A | 2 (7%) | 0 (0%) | 2 (11%) | |
| Days from transplantation to enrollment, median (IQR) | 0.5 (0-5) | 0 (0-7) | 1 (0-4) | .40 |
ALL indicates acute lymphocytic leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndromes; MPN, myeloproliferative neoplasms; BM, bone marrow; PBPC, peripheral blood progenitor cell; KPS, Karnofsky performance score; DRI, Disease Risk Index.